Aims and Scope
Clinical Genitourinary Cancer is a peer-reviewed medical journal published by Elsevier, and previously by CIG Media Group (Cancer Information Group). The journal publishes articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary cancers. The journal was previously published as Clinical Prostate Cancer through September 2005.
Key Metrics
5.5
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.9
5-Year SI
5-year SI
- N/A 2-year SI
- 0.85 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q2
Urology
SJR
- Q1 Urology
- Q2 Oncology
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.97
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
3 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
51%
4 to 6 months
34%
7 to 9 months
12%
Above 9 months
3%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Cancer
- Neuroendocrine tumors
- Prostate cancer
- Progression-free survival
- Lymph node
- Magnetic resonance imaging
- Prostate-specific antigen
- Toxicity
- Confidence interval
- Overall survival
- Bladder cancer
- Nivolumab
- Renal carcinoma
- Chemoradiotherapy
- Quality of life
- Artificial intelligence
- Prostatectomy
- Adjuvant
- Body mass index
- Cryotherapy
Journal Specifications
| Overview | |
| Publisher | CIG MEDIA GROUP, LP |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2002 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Clinical Genitourinary Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Robot-assisted cystectomy in patients with previous pelvic irradiation: A comprehensive systematic review and single-arm meta-analysis
- 1 Nov 24
- Clinical Genitourinary Cancer
-
Full paper
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study
- 1 Nov 24
- Clinical Genitourinary Cancer
-
Full paper
Prognostic Impact of IMDC Category Shift from Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study
- 1 Nov 24
- Clinical Genitourinary Cancer
-
Full paper
Development and validation of prognostic model for metastatic castration-resistant prostate cancer patients treated with first-line abiraterone or enzalutamide.
- 1 Nov 24
- Clinical Genitourinary Cancer
-
Full paper
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials
- 1 Nov 24
- Clinical Genitourinary Cancer
-
Full paper
Safety and Efficacy of 177Lu-PSMA Therapy Following 223Radium Treatment: A Retrospective Multinational Real-World Analysis
- 1 Nov 24
- Clinical Genitourinary Cancer
Scite analysis
Powered by scite_
2.6k articles received 24.5k citations see all
- 1,175 Supporting
- 22,548 Mentioning
- 196 Contrasting
Editorial notices
- 0 Retractions
- 1 Withdrawals
- 0 Corrections
- 4 Errata
- 0 Expression of Concern
FAQs
How long has Clinical Genitourinary Cancer been actively publishing?
Clinical Genitourinary Cancer has been in operation since 2002 till date.
What is the publishing frequency of Clinical Genitourinary Cancer ?
Clinical Genitourinary Cancer published with a Bi-monthly frequency.
How many articles did Clinical Genitourinary Cancer publish last years ?
In 2023, Clinical Genitourinary Cancer published 245 articles.
What is the eISSN & pISSN for Clinical Genitourinary Cancer ?
For Clinical Genitourinary Cancer,eISSN is 1938-0682 and pISSN is1558-7673.
What is Citescore for Clinical Genitourinary Cancer ?
Citescore for Clinical Genitourinary Cancer is 5.5.
What is SNIP score for Clinical Genitourinary Cancer ?
SNIP score for Clinical Genitourinary Cancer is 0.97.
What is the SJR for Clinical Genitourinary Cancer ?
SJR for Clinical Genitourinary Cancer is Q2.
Who is the publisher of Clinical Genitourinary Cancer ?
CIG MEDIA GROUP, LP is the publisher of Clinical Genitourinary Cancer.